Ductal adenocarcinoma of the prostate is an unusual subtype that may be associated with a more aggressive clinical course, and is less responsive to conventional therapies than the more common prostatic acinar adenocarcinoma. However, given its frequent association with an acinar component at prostatectomy, some have challenged the concept of prostatic ductal adenocarcinoma as a distinct clinicopathologic entity. We studied the occurrence of the TMPRSS2-ERG gene fusion, in 40 surgically resected ductal adenocarcinoma cases, and in their associated acinar component using fluorescence in situ hybridization. A group of 38 'pure' acinar adenocarcinoma cases matched with the ductal adenocarcinoma group for pathological grade and stage was studied as a control. Compared with the matched acinar adenocarcinoma cases, the TMPRSS2-ERG gene fusion was significantly less frequently observed in ductal adenocarcinoma (45 vs 11% of cases, P ¼ 0.002, Fisher's exact test). Here, of the ductal adenocarcinoma cases with the gene fusion, 75% were fused through deletion, and the remaining case was fused through translocation. The TMPRSS2-ERG gene fusion was also rare in the acinar component of mixed ductal-acinar tumors when compared with the pure acinar adenocarcinoma controls (5 vs 45%, P ¼ 0.001, Fisher's exact test). In 95% of the ductal adenocarcinoma cases in which a concurrent acinar component was analyzed, there was concordance for presence/absence of the TMPRSS2-ERG gene fusion between the different histologic subtypes. In the control group of pure acinar adenocarcinoma cases, 59% were fused through deletion and 41% were fused through translocation. The presence of the TMPRSS2-ERG gene fusion in some cases of prostatic ductal adenocarcinoma supports the concept that ductal adenocarcinoma and acinar adenocarcinoma may be related genetically. However, the significantly lower rate of the gene fusion in pure ductal adenocarcinoma cases underscores the fact that genetic and biologic differences exist between these two tumors that may be important for future therapeutic strategies.
Ductal adenocarcinoma of the prostate is an unusual subtype that may be associated with a more aggressive clinical course, and is less responsive to conventional therapies than the more common prostatic acinar adenocarcinoma. However, given its frequent association with an acinar component at prostatectomy, some have challenged the concept of prostatic ductal adenocarcinoma as a distinct clinicopathologic entity. We studied the occurrence of the TMPRSS2-ERG gene fusion, in 40 surgically resected ductal adenocarcinoma cases, and in their associated acinar component using fluorescence in situ hybridization. A group of 38 'pure' acinar adenocarcinoma cases matched with the ductal adenocarcinoma group for pathological grade and stage was studied as a control. Compared with the matched acinar adenocarcinoma cases, the TMPRSS2-ERG gene fusion was significantly less frequently observed in ductal adenocarcinoma (45 vs 11% of cases, P ¼ 0.002, Fisher's exact test). Here, of the ductal adenocarcinoma cases with the gene fusion, 75% were fused through deletion, and the remaining case was fused through translocation. The TMPRSS2-ERG gene fusion was also rare in the acinar component of mixed ductal-acinar tumors when compared with the pure acinar adenocarcinoma controls (5 vs 45%, P ¼ 0.001, Fisher's exact test). In 95% of the ductal adenocarcinoma cases in which a concurrent acinar component was analyzed, there was concordance for presence/absence of the TMPRSS2-ERG gene fusion between the different histologic subtypes. In the control group of pure acinar adenocarcinoma cases, 59% were fused through deletion and 41% were fused through translocation. The presence of the TMPRSS2-ERG gene fusion in some cases of prostatic ductal adenocarcinoma supports the concept that ductal adenocarcinoma and acinar adenocarcinoma may be related genetically. However, the significantly lower rate of the gene fusion in pure ductal adenocarcinoma cases underscores the fact that genetic and biologic differences exist between these two tumors that may be important for future therapeutic strategies. Keywords: Prostatic adenocarcinoma; ductal adenocarcinoma; endometrioid; TMPRSS2-ERG; gene fusion Ductal adenocarcinoma of the prostate is an unusual subtype, accounting in its pure form for 0.4% of all prostate cancer, and occurring as a mixed tumor with the more common prostatic acinar adenocarcinoma in up to 5% of all radical prostatectomy cases. 1,2 First described nearly 40 years ago, these tumors are characterized classically by large periurethral ductal structures filled with papillary fronds or cribriform proliferations lined by columnar epithelium. 3 In contrast to the more common acinar adenocarcinoma, prostatic ductal adenocarcinomas are often grossly visible to urologists on cystoscopy because of their central location within the gland and their occasional protrusion from the prostatic verumontanum. 1 Historically, clinical evidence supporting the distinction of ductal adenocarcinoma from acinar adenocarcinoma, has been the fact that the ductal adenocarcinoma cases are typically more aggressive tumors than their acinar counterparts, presenting at higher clinical stage and less responsive to traditional hormonal, radiation and radical surgical therapies in a handful of prior studies. [4] [5] [6] [7] However, since the early description of ductal adenocarcinoma, it has become clear that there is a more clinical overlap between ductal adenocarcinoma and acinar adenocarcinoma than was originally thought. In radical prostatectomy specimens, ductal adenocarcinoma occurs with a concurrent conventional acinar component in the majority of cases, making these mixed tumors much more common than pure ductal adenocarcinoma. 5 Much like acinar adenocarcinoma, tumors with the morphologic features of ductal adenocarcinoma may occur in peripheral locations. Additionally, a number of recent studies have challenged early reports of the ductal adenocarcinoma's resistance to traditional therapeutic strategies. 2, 8 Given the temporal and clinical overlap between these two variants of prostate cancer, some investigators have questioned whether ductal adenocarcinoma represents a truly distinct clinicopathologic entity, or whether these tumors are simply a morphologic variant in the spectrum of conventional acinar adenocarcinoma. 2 Recently, a bioinformatics approach uncovered a gene rearrangement present in 40-60% of conventional prostatic acinar adenocarcinoma cases, making it the most common rearrangement identified in human cancer to date. 9 This rearrangement occurs between an androgen-regulated gene, TMPRSS2 (transmembrane protease serine 2, 21q22.3) and an ETS transcription factor family member, most commonly ERG (v-ets erythroblastosis virus E26 oncogene homolog, 21q22.2), resulting in a gene fusion product. 10 This gene fusion can occur through a small deletion on chromosome 21 (seen approximately in two thirds of the acinar cases) or through a translocation. 11 In either type of the rearrangement, ERG is brought under the control of an androgen-regulated promoter and over expression of the protein ensues. Although the clinicopathologic significance of this genetic rearrangement has remained elusive, it is clear that TMPRSS2-ERG rearrangements are specific and sensitive for prostatic acinar adenocarcinoma. 12 The rearrangement may also be seen in concurrent highgrade prostatic intraepithelial neoplasia lesions, suggesting that it is a clonal and early pathogenic event in prostatic acinar adenocarcinoma. 13 Despite the numerous studies of TMPRSS2-ERG gene fusions in prostatic acinar adenocarcinoma, no studies to date have examined the occurrence of this rearrangement in prostatic ductal adenocarcinoma. Indeed, documentation of the TMPRSS2-ERG gene fusion in ductal adenocarcinoma might help resolve the continuing debate over whether prostatic ductal adenocarcinoma represents a truly distinct clinicopathologic entity. Here, we studied the rate of TMPRSS2-ERG gene fusions in 40 cases of ductal adenocarcinoma, and in a control group of pathologic grade-and stage-matched acinar adenocarcinoma cases by fluorescence in situ hybridization (FISH). We report that although the TMPRSS2-ERG fusions do occur in ductal adenocarcinoma, they are considerably less frequent in these tumors than in their acinar counterparts, suggesting that significant genetic and potential biologic differences may exist between these two prostate tumor types. Such differences may be important for guiding future treatments of prostatic ductal adenocarcinoma.
Materials and methods

Tissue Selection
A tissue microarray was constructed manually from 40 radical prostatectomy specimens with ductal adenocarcinoma, retrieved from the surgical pathology and consultation files of the Johns Hopkins Hospitals from 1984-2005. In 52% (21/40) of the ductal adenocarcinoma cases, a concurrent acinar component was present and included in the tissue microarray. In each case, quadruplicate 0.6 mm cores were punched from the ductal adenocarcinoma component, the acinar component (when present) and the surrounding benign prostatic tissue, with up to 16 total cores from each patient represented on the array. The ductal and acinar adenocarcinoma components were considered geographically separate primaries when the ductal adenocarcinoma and acinar adenocarcinoma tumor foci were separated by at least 5 mm in all dimensions.
Fifteen 'pure' acinar adenocarcinoma cases (Gleason pattern 4) were also included on the ductal adenocarcinoma tissue microarray as an internal control group. To provide additional pure acinar adenocarcinoma controls, an additional 23 acinar adenocarcinoma cases were selected for matched pathologic stage from a second tissue microarray, constructed from a PSA-era prostatectomy cohort (cases dating from 1993 to 2000). Overall, the 38 pure acinar adenocarcinoma controls were matched with the ductal adenocarcinoma group for pathological stage (39% pT2, 58% pT3) and grade (68% Gleason 7, 31% Gleason 8-9) ( Table 1) .
Fluorescence In Situ Hybridization FISH, using a break-apart probe for 5 0 and 3 0 ERG, was performed on the two tissue microarrays. Briefly, sections of 4 mm-thick, paraffin-embedded (Figure 2 , bottom row, both panels). Any case with one of the above ERG signal abnormalities in Z10% of the nuclei was scored as a fusion case and classified accordingly. Digitally scanned adjacent hematoxylin and eosin serial sections were available for side-by-side comparison with the FISH image to localize tumor cells, and a Gleason grade was assigned to each sampled core. Five cases of benign prostatic epithelium were scored on each tissue microarray as a negative control.
FISH scoring was conducted using a 100x oil immersion lens on an Olympus AX-70 fluorescence microscope (Olympus, Center Valley, PA) equipped with appropriate filters. For photomicrographs, images were captured using a Nikon E400 fluorescence microscope equipped with a Nikon DXM1200 camera (Nikon Instruments, Melville, NY) and the SPOT Advanced digital imaging software (Diagnostic Instruments, Inc., Sterling Heights, MI).
Statistical Analysis
The findings were analyzed using the Stata 9.2. (StataCorp, College Station, TX) software package. An appropriate pathologic grade and stage matching of the ductal adenocarcinoma cases and the acinar adenocarcinoma controls was tested using the Kruskal-Wallis test for non-parametric one-way analysis of variance by ranks. Fisher's exact test was used to compare frequency of the TMPRSS2-ERG fusion in ductal adenocarcinoma cases vs acinar adenocarcinoma controls.
Results
Here, of the 40 ductal adenocarcinoma cases, 38 were evaluable by FISH for ERG gene rearrangements (95%). Overall, 11% (4/38) of the ductal adenocarcinomas showed the TMPRSS2-ERG gene fusion, with 75% (3/4) showing the deletion and 25% (1/4) showing the translocation (Table 2, Figures 1 and 2) . No cases of duplication/polyploidy of the fusion were observed in the ductal adenocarcinoma group. In 55% (21/38) of the evaluable ductal adenocarcinoma cases, a concurrent acinar component was present for evaluation as well. Although represented on separate cores in the tissue microarray, the ductal adenocarcinoma and acinar adenocarcinoma components were geographically separate primaries (separated by at least 5 mm in all dimensions), in the radical prostatectomy specimen in only 19% (4/21) of the cases (Figure 1 ). In 67% (14/21) of the cases, the two morphologies commingled and appeared to represent a single primary tumor (Figure 2) , and in 14% of the cases (3/21), it was not possible to tell whether the components were separated spatially. In all the 21 cases, the sampled acinar component consisted primarily of poorly formed or cribriform glands diagnostic of Gleason pattern 4 carcinoma (Gleason score 7-8). As seen in the ductal adenocarcinoma component, TMPRSS2-ERG gene fusion was also rare in the acinar component of mixed ductal-acinar adenocarcinomas (1/21 cases, 5%). In 95% of the ductal adenocarcinoma cases in which a concurrent acinar component was available for analysis (20/21), there was concordance for presence/absence of the TMPRSS2-ERG gene fusion between the different histologic subtypes (Table 3 ). The only discordant case (Case 30, Table 3, Figure 1 ) showed gene fusion through deletion in the ductal adenocarcinoma component and had no evidence of gene rearrangement in the cribriform acinar adenocarcinoma component. The ductal adenocarcinoma and acinar adenocarcinoma components appeared to be spatially separate primaries in this case (Table 3, Figure 1 ). In 95% (19/20) of the concordant cases, no gene rearrangement was detected, whereas in the remaining concordant case, a gene fusion through translocation was detected in the ductal adenocarcinoma as well as in the poorly formed glands of the acinar adenocarcinoma (Case 16, Table 3, Figure 2 ). In this case, the ductal adenocarcinoma and acinar adenocarcinoma components were commingled spatially.
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Here, in the control group of 38 grade-and stagematched pure acinar adenocarcinoma cases, 45% (17/38) had the gene fusion with 53% (9/17) showing the deletion, 6% (1/17) showing a duplicated deletion (deletion with polyploidy) and 41% (7/17) showing the translocation (Table 2 ). All sampled tumor cores from the acinar adenocarcinoma control cases showed predominantly poorly formed or cribriform carcinoma glands and all were graded as primary Gleason pattern 4 carcinoma (Gleason score 7-8). Compared with the matched acinar adenocarcinoma control cases, the TMPRSS2-ERG gene fusion was significantly less frequently observed in ductal adenocarcinoma (P ¼ 0.002, Fisher's exact test), as well as, in the acinar adenocarcinoma component of mixed ductalacinar adenocarcinoma tumors (P ¼ 0.001, Fisher's exact test).
Discussion
Perhaps the most compelling reason to subclassify prostatic carcinoma into ductal and acinar variants is that ductal adenocarcinoma has been found to have a clinically more aggressive course than the typical Gleason pattern 3 acinar adenocarcinoma. [4] [5] [6] Although many of the original studies were conducted in pre-PSA era cohorts, a handful of more recent studies based on prostate needle biopsy with follow-up radical prostatectomy have shown similar results. 7 Only rare reports have suggested that ductal adenocarcinoma may have a less aggressive course than typical acinar adenocarcinoma.
14 However, because of the infrequent occurrence of ductal adenocarcinoma, studies with clinical follow-up of large cohorts, as seen in acinar adenocarcinoma, have not occurred. Although only acinar adenocarcinoma is included in Gleason's prostate carcinoma grading system, the current consensus is to treat ductal adenocarcinoma as if it is a Gleason 4 þ 4 ¼ 8 carcinoma. 15 This is in part based on evidence from a needle biopsy study that suggested that the prognosis of surgically resected ductal adenocarcinoma cases was between that of a Gleason score 7 and Gleason score 8 acinar adenocarcinoma. 7 Despite these important clinical differences between ductal and acinar adenocarcinoma, to our knowledge, the two tumor types have not been compared on a molecular-genetic level. Although ductal adenocarcinoma and acinar adenocarcinoma may occur together in as many as 5% of radical prostatectomies, no prior studies have examined whether there is a clonal relationship between these tumor components. Based on morphologic observations, the ductal and acinar tumor components in mixed prostate carcinoma cases are more often commingled intimately than geographically separate; a finding that would suggest that these components are likely genetically related, at least in a subset of cases. 16 In this study, we also found that in mixed ductal-acinar tumors, the two components were intermingled. Further, the very presence of the TMPRSS2-ERG rearrangement in 11% of the ductal adenocarcinoma cases suggests that at least some cases with the morphologic features of ductal adenocarcinoma may share some of the same early pathogenetic aberrations with acinar adeno- TMPRSS2-ERG in prostatic ductal adenocarcinoma TL Lotan et al carcinoma cases. Additionally, in 95% of the mixed ductal-acinar adenocarcinoma cases there was concordance for presence/absence of the TMPRSS2-ERG rearrangement between the ductal and acinar components of the tumor in a given case. As the vast majority of these cases did not have the TMPRSS2-ERG rearrangement, this data certainly does not prove a genetic relationship between the acinar and ductal tumor components; however, it is not inconsistent with this hypothesis. To date, the role of the TMPRSS2-ERG gene rearrangement in the initiation and progression of prostate carcinoma remains unclear. Early studies of the rearrangement suggested that the presence of the gene fusion was associated with higher stage and Gleason grade disease, and shorter interval to biochemical recurrence. [17] [18] [19] [20] However, recent larger studies in surgical cohorts have consistently found an inverse relationship between Gleason grade and rates of gene fusion, and no consistent relationship with prognosis, measured either by biochemical recurrence or overall survival has emerged. 21, 22 ERG over expression in transgenic mouse models causes prostatic intraepithelial neoplasia, but not invasive cancer, suggesting that TMPRSS2-ERG fusion may not be sufficient for transformation to an invasive phenotype. 23 In vitro experiments using ERG over expression or knockdown in cell lines suggest that ERG may play a role in the activation of multiple cellular programs modulating tumor cell invasion, as well as in the activation of the oncogene C-MYC. [23] [24] [25] However, no dramatic role for the TMPRSS2-ERG fusion in prostate tumor initiation or progression has emerged.
Even in light of the inverse relationship with Gleason grade, the finding in this study that only 11% of the ductal adenocarcinoma cases showed the rearrangement is somewhat surprising. Most large studies of acinar adenocarcinoma have found the percent of rearranged cases to hover around 40-50%, with higher Gleason score cases showing a minimum of 25% fusion rates in one study. [17] [18] [19] 21, 22, 26, 27 In our PSA-era cohort of gradematched pure acinar adenocarcinoma controls (Gleason 7-8), we found 45% of cases had the rearrangement, a somewhat higher fraction than reported by Fine et al for the same grade, but one that is comparable with the overall rates of fusion reported in most surgical cohorts. Compared with our grade-matched pure acinar adenocarcinoma controls, the finding of only 11% rearrangement in the ductal carcinoma group is highly significant. Given that a subset of our pure acinar adenocarcinoma controls were embedded in the same ductal adenocarcinoma tissue microarray block, and these cases showed a much higher rate of TMPRSS2-ERG rearrangement, it appears unlikely that the low rate of rearrangement in the ductal adenocarcinoma cases is an artifact related to FISH or tissue microarray preparation.
Ultimately, the biologic explanation for the low rate of TMPRSS2-ERG fusions in prostatic ductal carcinoma requires further study, and may not emerge until we have a better understanding of the role of the fusion in prostate cancer initiation and progression. At the very least, our findings support the emerging concept that TMPRSS2-ERG fusion is less common in prostate tumors that appear more aggressive by traditional pathologic measures (ie, Gleason grade). Whether this genetic difference ever translates into an independent predictor of clinical outcome remains unclear. Similarly, how this inverse relationship between Gleason grade and frequency of TMPRSS2-ERG rearrangement can be explained, by what we know about the biological activity of ERG, is not evident. Here, of note, the frequency of TMPRSS2-ERG rearrangement in the acinar component of the mixed tumors in our series was also significantly lower than the frequency observed in the pathologic grade-matched pure acinar adenocarcinomas (45 vs 5%). This may be additional, though indirect, evidence for a genetic relationship between the acinar and ductal components in mixed tumors. Further, this data suggests that the pathogenetic events leading to mixed ductal-acinar tumors may be distinct from those leading to pure acinar adenocarcinomas. Such differences may have important biologic and clinical relevance when the pathogenic role of the TMPRSS2-ERG gene rearrangement is more fully understood.
